Health and Environmental Sciences Institute Thrive Advisory board

Description

WHAT IS IT?
Treatment related adverse impacts on patient quality of life are not unique to any one oncologic drug class or therapeutic approach and challenge our ability to support the best possible cancer patient outcomes. Despite the opportunity to do better, funding for research in this critical arena has been limited.

THRIVE offers funding for basic science, clinical, and translational research that enhances our ability to predict when and how adverse effects may occur in patients who have received cancer treatment and supports the development of approaches to avoid or lessen these effects. By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities.

Period	1 Sept 2021 → …
Degree of Recognition	International